Skip to content
Participate in our active studiesSubscribe to our Mailing List
AB Science
Masitinib and AB8939 – Two compounds with breakthrough mechanism of action
AB Science AB Science
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in neurodegenerative disorders
    • Masitinib in inflammatory diseases
    • Masitinib in oncology
    • Masitinib in viral diseases
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Alzheimer’s Disease
      • Indolent Systemic Mastocytosis
      • Mast Cell Activation Syndrome
      • Severe Asthma
      • Prostate Cancer
      • Pancreatic Cancer
      • COVID-19
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webconference replay
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
    • Events
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact
  • English
  • French
Search:
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in neurodegenerative disorders
    • Masitinib in inflammatory diseases
    • Masitinib in oncology
    • Masitinib in viral diseases
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Alzheimer’s Disease
      • Indolent Systemic Mastocytosis
      • Mast Cell Activation Syndrome
      • Severe Asthma
      • Prostate Cancer
      • Pancreatic Cancer
      • COVID-19
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webconference replay
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
    • Events
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact

Category Archives: News

You are here:
  1. Home
  2. Category "News"

Summary of webcast with Key Opinion Leaders on masitinib Phase 2B/3 results in Progressive Forms of MS

2020By Alexis BERNARDMarch 9, 2020

09/03/2020 – AB Science provides a summary of the live webcast held on March 6 2020 with key opinion leaders on progressive froms of multiple sclerosis

New fundraising of EUR 12.3 million

2020By Alexis BERNARDMarch 1, 2020

02/03/2020 – AB Science announces a new fundraising of EUR 12.3 million

Positive top-line Phase 2B/3 results for masitinib in progressive forms of MS

2020By Alexis BERNARDFebruary 20, 2020

20/02/2020 – AB Science announces positive top-line Phase 2B/3 results for oral masitinib in progressive forms of multiple sclerosis

FDA green-lights U.S. patient enrollment in masitinib phase 3 study in metastatic castrate-resistant prostate cancer

2020By Alexis BERNARDJanuary 8, 2020

08/01/2020 – FDA green-lights U.S. patient enrollment in masitinib phase 3 study following IND clearance in metastatic castrate-resistant prostate cancer eligible to chemotherapy

Publication of new results in in the peer-reviewed journal Glia that further support masitinib’s potential mode of action in ALS

2019By Alexis BERNARDDecember 23, 2019

23/12/2019 – AB Science announces publication of new results in the peer-reviewed journal Glia that further support masitinib’s potential mode of action in ALS

Publication of three AB8939 scientific abstracts in the special ASH Annual Meeting issue of Blood

2019By Alexis BERNARDDecember 9, 2019

09/12/2019 – AB Science announces publication of three AB8939 scientific abstracts in the special ASH Annual Meeting issue of Blood

Webcast on masitinib in severe asthma on Monday, December 2, 2019

2019By Alexis BERNARDNovember 26, 2019

27/11/2019 – AB Science will host a live webcast on masitinib in severe asthma on Monday December 2, 2019

Summary of webcast with Key Opinion Leaders on Indolent Systemic Mastocytosis

2019By Alexis BERNARDNovember 25, 2019

25/11/2019 – AB Science provides a summary of the live webcast on November 20 with key opinion leaders on Indolent Systemic Mastocytosis (ISM)

Clarification regarding the article in the newspaper Les Echos related to the investigation by the French market authorities

2019By Alexis BERNARDNovember 22, 2019

22/11/2019 – AB Science provides clarification regarding the article in the newspaper Les Echos related to the investigation by the French market authorities

Positive top-line Phase 3 results for masitinib in severe asthma

2019By Alexis BERNARDNovember 7, 2019

07/11/2019 – AB Science announces positive top-line phase 3 results for oral masitinib in severe asthma

←1
2345678
…910111213…
1415
16→
AB Science
© AB Science – All right reserved
Go to Top